Clinical Data and Safety Management Center for NIAID-supported Allergic and Autoimmune Research
Official title: RhoFED CDSMC
Funded at Rho Federal Systems Division, INC. · NIH-11595626 · Data updated 2026-11-12
A dedicated center helps manage and safely support NIAID-funded clinical studies on allergic diseases, asthma, and autoimmune conditions, using modern data systems and biospecimen tracking.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rho Federal Systems Division, INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project start | May 8, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $461,320 |
| NIH project number | 3U01AI178773-04S2 |
| Project ID | NIH-11595626 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients enrolled in NIAID-supported clinical trials on allergic diseases, asthma, and autoimmune disorders may indirectly benefit through better trial management and safety oversight.
✕Less likely to help
Healthy volunteers or general patients not enrolled in NIAID-funded trials may not directly benefit from this center’s activities.
What this research studies
This project provides centralized data management, safety monitoring, and biospecimen tracking for NIAID clinical trials focused on allergic diseases, asthma, and immune-related disorders. It emphasizes adopting current best practices in trial operations while slowly integrating innovative technologies. The center assembles four cores to streamline administrative tasks, data handling, safety events, and sample tracking to support researchers and participants. By maintaining continuity with prior work and embracing new tools, it aims to improve the reliability and efficiency of clinical research. Participants would benefit from robust safety oversight and higher-quality data that support trustworthy study results.
Why it matters
Potential benefit: Improved safety monitoring and data quality could lead to faster, more reliable results for treatments of allergic and autoimmune diseases.
How similar studies have gone: Past CDSMC efforts have evolved with technology to enhance trial operations and data integrity, suggesting positive potential for continued success.
Where this research is happening
-
Rho Federal Systems Division, INC.
Durham, United States Active
Researchers
- Principal investigator: Dunaway, Lars — Rho Federal Systems Division, INC.
- Study coordinator: Dunaway, Lars
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.